Investigation into Steelcase, LAVA Therapeutics, and Enzo Biochem on Behalf of Shareholders

Friday, Aug 8, 2025 1:19 am ET1min read

Halper Sadeh LLC is investigating Steelcase Inc., LAVA Therapeutics N.V., and Enzo Biochem, Inc. for potential securities law violations and breaches of fiduciary duties to shareholders. The investigations relate to Steelcase's sale of HNI Corporation, LAVA's sale to XOMA Royalty Corporation, and Enzo's sale to Battery Ventures. The law firm may seek increased consideration for shareholders, additional disclosures, and other relief. Shareholders are encouraged to contact Halper Sadeh LLC for legal rights and options.

Halper Sadeh LLC, a prominent investor rights law firm, has initiated investigations into potential securities law violations and breaches of fiduciary duties by the boards of Steelcase Inc., LAVA Therapeutics N.V., and Enzo Biochem, Inc. The investigations pertain to recent mergers and acquisitions involving these companies.

Steelcase Inc. and HNI Corporation
Steelcase Inc. (NYSE: SCS) recently sold itself to HNI Corporation for $7.20 in cash and 0.2192 shares of HNI common stock per share of Steelcase. Halper Sadeh LLC is examining whether the sale price and terms offer fair value to Steelcase shareholders. The firm is considering seeking increased consideration, additional disclosures, or other relief on behalf of shareholders [3].

LAVA Therapeutics N.V. and XOMA Royalty Corporation
LAVA Therapeutics N.V. (Nasdaq: LVTX) has agreed to be acquired by XOMA Royalty Corporation (Nasdaq: XOMA) for $1.16 in cash per share, plus up to $0.08 per share and a non-transferable contingent value right per share. Halper Sadeh LLC is investigating whether the transaction terms provide fair value to LAVA shareholders. The firm may seek additional disclosures or other remedies to protect shareholders' interests [3].

Enzo Biochem, Inc. and Battery Ventures
Enzo Biochem, Inc. (OTCMKTS: ENZB) has agreed to be acquired by Battery Ventures for $0.70 in cash per share. Halper Sadeh LLC is examining whether the sale price and terms offer fair value to Enzo shareholders. The firm may seek increased consideration, additional disclosures, or other relief on behalf of shareholders [3].

Shareholders of these companies are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options. The firm operates on a contingent fee basis, meaning shareholders do not bear out-of-pocket expenses for legal fees or costs.

References:
[1] https://www.prnewswire.com/news-releases/shareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-steelcase-inc-nyse-scs-302524834.html
[2] https://www.brodskysmith.com/cases/lava-therapeutics-n-v-nasdaq-lvtx/
[3] https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-scs-lvtx-enzb-on-behalf-of-shareholders-302524965.html

Investigation into Steelcase, LAVA Therapeutics, and Enzo Biochem on Behalf of Shareholders

Comments



Add a public comment...
No comments

No comments yet